Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Group 1: Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Group 2: Legal Proceedings - The lawsuit is pending in the U.S. District Court for the Central District of California, with investors having until September 22, 2025, to seek lead plaintiff status [2]. - The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased RxSight securities [2]. Group 3: Financial Performance and Stock Impact - RxSight experienced a slowdown in LAL utilization, first noted in 2024, which was not disclosed to investors during the relevant period [4]. - On April 3, 2025, RxSight cut its 2025 full-year revenue forecast, leading to a stock price decline of approximately 38%, from $26.12 to $16.21 per share [5]. - A further revenue forecast cut on July 8, 2025, attributed to slower LAL utilization and adoption challenges, resulted in another 38% decline in stock price, from $12.79 to $7.95 per share [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against RxSight, Inc. due to allegations of misleading statements and failure to disclose significant operational challenges that have negatively impacted the company's financial performance [4][6]. Group 1: Legal Investigation and Class Action - The firm is reminding investors of the September 22, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against RxSight [4]. - Investors who suffered losses in RxSight between November 7, 2024, and July 8, 2025, are encouraged to contact the firm to discuss their legal rights [1][9]. Group 2: Allegations Against RxSight - The complaint alleges that RxSight and its executives violated federal securities laws by making false or misleading statements regarding the company's sales and product demand [6]. - Specific allegations include that the company faced "adoption challenges" leading to declines in sales and utilization, overstated demand for its products, and was unlikely to meet its previously issued financial guidance for fiscal year 2025 [6]. Group 3: Financial Performance and Market Reaction - On July 8, 2025, RxSight reported preliminary second quarter 2025 financial results, showing significant declines in LDD sales, LAL utilization, and overall revenue, along with a lowered full-year guidance by approximately $42.5 million at the midpoint [7]. - Following this announcement, RxSight's stock price fell by $4.84, or 37.8%, closing at $7.95 per share on July 9, 2025, amid unusually heavy trading volume [7].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of RxSight, Inc. during the specified class period of their potential entitlement to compensation through a class action lawsuit [1][4]. Group 1: Class Action Details - The class period for the lawsuit is from November 7, 2024, to July 8, 2025, and the lead plaintiff deadline is September 22, 2025 [1][2]. - Investors can join the class action without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must act by the lead plaintiff deadline to represent other class members [2][6]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise and reputation [3]. Group 3: Allegations Against RxSight - The lawsuit alleges that RxSight made false and misleading statements regarding its sales and utilization, overstated product demand, and was unlikely to meet its financial guidance for fiscal year 2025 [4]. - The claims suggest that the positive statements made by RxSight about its business and prospects were materially misleading and lacked a reasonable basis [4].

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in RxSight, Inc. ("RxSight, Inc." or the "Company") (NASDAQ: RXST) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of RxSight, Inc. investors who were adversely affected by alleged securities fraud between November 7, 2024 and July 8, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/rxsight-inc-lawsuit- ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of RxSight, Inc. regarding a class action lawsuit due to alleged misleading statements and undisclosed issues affecting the company's performance during a specified class period [1][2]. Summary by Relevant Sections Allegations - The complaint alleges that during the class period from November 7, 2024, to July 8, 2025, RxSight faced "adoption challenges" and structural issues leading to declines in sales and utilization [1]. - It is claimed that the defendants overstated the demand for RxSight's products [1]. - As a result of these issues, RxSight is unlikely to meet its previously issued financial guidance for fiscal year 2025 [1]. - The positive statements made by the defendants regarding the company's business and prospects were materially misleading and lacked a reasonable basis [1]. Class Action Details - Shareholders who purchased shares of RXST during the specified class period are encouraged to register for the class action, with a deadline of September 22, 2025, to seek lead plaintiff status [2]. - Registered shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [2]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3].

Core Viewpoint - A shareholder has filed a securities class action lawsuit against RxSight, Inc. for allegedly overstating product demand and failing to disclose sales declines due to adoption challenges and structural issues [1][3]. Summary by Relevant Sections Lawsuit Details - The lawsuit is on behalf of investors who purchased or acquired RxSight securities between November 7, 2024, and July 8, 2025 [1]. - Defendants are accused of misrepresenting the demand for RxSight's products and not revealing significant challenges affecting sales [3]. Legal Process - Investors wishing to serve as lead plaintiffs must file necessary documents by September 22, 2025 [4]. - Participation in the lawsuit does not require serving as a lead plaintiff, and all representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [4]. Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has a strong track record in class action litigation [5].

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Group 1: Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Group 2: Legal Issues - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, representing investors who purchased RxSight securities [2]. - The company allegedly failed to disclose "adoption challenges" for its products, which contributed to a slowdown in LAL utilization first noted in 2024 [4]. Group 3: Stock Performance - On April 3, 2025, RxSight cut its 2025 full-year revenue forecast, leading to a stock price drop of approximately 38%, from $26.12 to $16.21 per share [5]. - A further revenue forecast cut on July 8, 2025, resulted in another 38% decline in stock price, from $12.79 to $7.95 per share [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against RxSight, Inc. due to allegations of false and misleading statements regarding the company's performance and financial guidance, particularly following a significant drop in stock price after disappointing financial results [2][4][5]. Group 1: Company Performance and Allegations - The complaint against RxSight alleges that the company and its executives violated federal securities laws by failing to disclose "adoption challenges" and structural issues that led to declines in sales and utilization [4]. - RxSight overstated the demand for its products, which resulted in the company being unlikely to meet its previously issued financial guidance for fiscal year 2025 [4]. - Following the release of preliminary second quarter 2025 financial results, RxSight reported significant declines in LDD sales, LAL utilization, and overall revenue, leading to a lowered full year 2025 guidance by approximately $42.5 million at the midpoint [5]. Group 2: Stock Market Reaction - On July 9, 2025, RxSight's stock price fell by $4.84, or 37.8%, closing at $7.95 per share, following the announcement of disappointing financial results and guidance [5]. Group 3: Legal Proceedings - Investors who purchased or acquired securities in RxSight between November 7, 2024, and July 8, 2025, are encouraged to discuss their legal rights and options, with a deadline of September 22, 2025, to seek the role of lead plaintiff in a federal securities class action [2][6].

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Legal Proceedings - Investors have until September 22, 2025, to request to lead the case, which is currently pending in the U.S. District Court for the Central District of California under the caption Makaveev v. RxSight, Inc., et al. [2]. Financial Performance - The company experienced a slowdown in LAL utilization, first noted in 2024, which was not disclosed to investors despite claims of strong sales [4]. - On April 3, 2025, RxSight cut its 2025 full-year revenue forecast, leading to a stock price drop of approximately 38%, from $26.12 to $16.21 per share [5]. - A further revenue forecast cut on July 8, 2025, attributed to slower LAL utilization and adoption challenges, resulted in another 38% decline in stock price, from $12.79 to $7.95 per share [6].

Core Viewpoint - A class action securities lawsuit has been filed against RxSight, Inc. due to alleged securities fraud affecting investors between November 7, 2024, and July 8, 2025 [1][2] Group 1: Allegations - The lawsuit claims that RxSight, Inc. faced "adoption challenges" and structural issues leading to declines in sales and utilization [2] - It is alleged that the demand for RxSight's products was overstated by the defendants [2] - The company is unlikely to meet its previously issued financial guidance for fiscal year 2025 as a result of these issues [2] - Positive statements made by the defendants regarding the company's business and prospects were materially misleading and lacked a reasonable basis [2] Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until September 22, 2025, to request to be appointed as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securing compensation for shareholders and has been recognized as one of the top securities litigation firms in the United States [4]